Business
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The hybrid meetings will take place virtually and in person at the Salt Palace Convention Center in Salt Lake City, February 2 – 6, 2022.\n\nTitle: Updated Interim Results from the Equate Study: Preliminary Safety and Efficacy of Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease\nFirst Author: Dr. John Koreth, associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School\nPoster Number: 372\n\nThe abstract highlights safety and tolerability, pharmacokinetic/pharmacodynamic and efficacy data from the ongoing EQUATE study in acute graft-versus-host disease (aGVHD) (NCT03763318). The data demonstrates promising outcomes in subjects with Grade III-IV aGVHD patients and supports the planned pivotal study of itolizumab in first-line aGVHD.\n\nTitle: Itolizumab, a Novel Targeted Anti-CD6 Therapy, Induces Cleavage of Cell Surface CD6 and Rapid Onset of Efficacy in Subjects with Newly Diagnosed Acute Graft-Versus-Host Disease\nFirst Author: Cherie Ng, Senior Director of Research, Equillium, Inc.\nPoster Number: 371\n\nThe abstract highlights data demonstrating a rapid and durable decrease in cell surface CD6 and a corresponding increase in serum CD6 in subjects with aGVHD. An association between itolizumab concentrations and clinical efficacy was observed, highlighting the importance of achieving high concentrations early in the treatment period to maximize a pharmacodynamic effect and efficacy.\n\nTitle: The CD6-ALCAM Pathway Promotes Effector T Cell Migration\nFirst Author: Valeria Marrocco, Scientist, Equillium, Inc.\nPoster Number: 362\n\nThe abstract outlines data that suggests the CD6-ALCAM pathway is important in the chemokine-driven migration of T cells through endothelial layers and that consequently, blockade of this pathway will not only inhibit T effector cell activity, but may aide in regulating T effecto...